Dr. Fanale on the Potential of Antibody-Drug Conjugates

Michelle A. Fanale, MD
Published: Tuesday, Feb 12, 2013

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of antibody-drug conjugates, as a new category of therapy for patients with cancer.

Brentuximab vedotin (Adcetris), the first FDA approved antibody-drug conjugate, is indicated to treat patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following progression on prior therapies. In addition to relapsed patients, Fanale anticipates potential for brentuximab as a frontline treatment. She believes the frontline administration of brentuximab plus chemotherapy may have the potential to prevent relapse.

Fanale adds that brentuximab sets the stage for the development of similar drug conjugates. These novel agents could herald a new era in cancer development, similar to the advent of monoclonal antibody therapies.

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of antibody-drug conjugates, as a new category of therapy for patients with cancer.

Brentuximab vedotin (Adcetris), the first FDA approved antibody-drug conjugate, is indicated to treat patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following progression on prior therapies. In addition to relapsed patients, Fanale anticipates potential for brentuximab as a frontline treatment. She believes the frontline administration of brentuximab plus chemotherapy may have the potential to prevent relapse.

Fanale adds that brentuximab sets the stage for the development of similar drug conjugates. These novel agents could herald a new era in cancer development, similar to the advent of monoclonal antibody therapies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x